MAIA Biotechnology, Inc. (MAIA) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 152.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: N/A
• EPS Growth: 23.55%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): -1.11
• Shares Outstanding: 26,157,787
• 10 Day Avg. Volume: 155,938
• 30 Day Avg. Volume: 152,204
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -3.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $14.00
• Price Target Upside: 695.45% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

MAIA Biotechnology shows potential with promising Phase 2 trial results that could expedite FDA approval. However, the company's financial performance is constrained by negative profitability and cash flows typical for early-stage biotech firms. Technical indicators show mixed signals, with a slight bearish trend but neutral RSI. Valuation remains challenging due to negative earnings, underscoring the stock's speculative nature.

MAIA Biotechnology, Inc. Business Overview & Revenue Model

Company Description

MAIA Biotechnology, Inc. (MAIA) is a clinical-stage biopharmaceutical company focused on developing innovative oncology treatments. The company specializes in advancing targeted therapies that address unmet medical needs in cancer treatment, particularly leveraging its proprietary technology platform to develop novel therapies for various types of cancer.

How the Company Makes Money

MAIA Biotechnology, Inc. makes money primarily through the development and commercialization of oncology therapies. The company's revenue model includes securing funding through partnerships, licensing agreements, and collaborations with other pharmaceutical companies. These partnerships often involve milestone payments, royalties, and upfront fees linked to the development and eventual commercialization of their drug candidates. Additionally, MAIA may also receive government grants or research funding to support its clinical trials and research activities. As the company progresses its drug candidates through clinical trials and towards regulatory approval, it aims to generate revenue through the successful commercialization of these therapies.

MAIA Biotechnology, Inc. Financial Statement Overview

Summary

MAIA Biotechnology is in a pre-revenue phase, with significant net losses and negative cash flow indicative of high R&D investment. The company has no debt, relying on equity financing, which is a positive aspect, but financial stability is precarious due to ongoing cash burn.

Income Statement

MAIA Biotechnology, Inc. has consistently reported no revenue, reflecting the company's status as a development-stage biotechnology firm. The net losses are significant and have increased over time, indicating higher operational costs as the company invests in R&D and other expenses. The absence of gross profit and negative EBIT and EBITDA margins further highlight the lack of profitability.

Balance Sheet

The company's balance sheet shows no debt, which is positive, but the equity has been fluctuating, recently improving to a positive figure. The company relies on equity financing to support its operations, as evidenced by the increase in stockholders' equity over time. However, the low equity ratio indicates a small buffer against liabilities, making the financial position somewhat precarious.

Cash Flow

MAIA's cash flow statement reflects significant negative operating cash flows, consistent with its developmental phase. The company has been financing its operations through equity, as shown by substantial financing cash flows. Free cash flow remains negative, indicating ongoing cash burn without generating operational cash inflows.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00	0.00	0.00
	EBIT
-18.38M	-20.18M	-16.18M	-7.79M	-6.98M	-6.92M
	EBITDA
-21.86M	-20.18M	-16.18M	0.00	0.00	242.00
	Net Income Common Stockholders
-25.94M	-19.77M	-15.81M	-13.29M	-6.67M	-6.49M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
663.46K	7.15M	10.95M	10.57M	663.46K	1.71M
	Total Assets
746.50K	7.57M	12.02M	11.33M	746.50K	1.73M
	Total Debt
463.75K	0.00	0.00	0.00	463.75K	35.17K
	Net Debt
-199.70K	-7.15M	-10.95M	-10.57M	-199.70K	-1.67M
	Total Liabilities
2.36M	7.09M	3.51M	2.15M	2.36M	409.74K
	Stockholders Equity
-3.34M	477.51K	8.51M	9.18M	-3.34M	-172.87K
Cash Flow		Free Cash Flow
-15.79M	-13.07M	-11.66M	-4.12M	-1.84M	-1.57M
	Operating Cash Flow
-15.79M	-13.07M	-11.66M	-4.12M	-1.84M	-1.57M
	Investing Cash Flow
3.92M	0.00	0.00	0.00	0.00	187.56K
	Financing Cash Flow
18.36M	9.27M	12.48M	14.03M	798.05K	2.22M

MAIA Biotechnology, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.76
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MAIA, the sentiment is Negative. The current price of 1.76 is above the 20-day moving average (MA) of 1.70, below the 50-day MA of 1.84, and below the 200-day MA of 2.58, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 44.79 is Neutral, neither overbought nor oversold. The STOCH value of 52.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MAIA.

MAIA Biotechnology, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MAIA	49 Neutral		―	-1131.02%	―	―	23.55%
Sector *	49 Neutral	$6.94B	0.66	-52.58%	2.47%	22.65%	0.94%
BLRX	48 Neutral	$12.61M	―	-184.09%	―	―	68.50%
CYCN	45 Neutral	$7.45M	―	-30.36%	―	―	86.52%
AFMD	42 Neutral	$13.52M	―	-151.46%	―	-95.23%	-325.89%
CLRB	35 Underperform	$17.00M	―	-4693.38%	―	―	56.38%
GRTX	31 Underperform	$2.50M	―	13.71%	―	―	80.99%

MAIA Biotechnology, Inc. Corporate Events

MAIA Biotechnology Updates Executive Compensation Packages

On February 1, 2025, MAIA Biotechnology, Inc. announced updates to the employment agreements of key executives, including Dr. Vlad Vitoc, Chairman and CEO, and Dr. Sergei Gryaznov, Chief Scientific Officer. These amendments included salary increases and revised bonus structures, enhancing their compensation packages based on performance objectives and corporate goals. The changes reflect a strategic move to retain top leadership talent and align executive incentives with company goals, potentially impacting the company’s operational strategy and competitive positioning in the biotech industry.

MAIA Biotechnology Reports Promising Phase 2 Trial Results

On February 4, 2025, MAIA Biotechnology announced positive updates from its Phase 2 THIO-101 trial for advanced non-small cell lung cancer. The trial showed a significant median overall survival of 16.9 months, suggesting a strong advantage over standard chemotherapy treatments. This development enhances MAIA’s regulatory strategy and could expedite FDA approval, marking a potential breakthrough for patients with limited treatment options.